Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights • Consolidated revenue increased 14% to $156 million • Clinical Services revenue increased 17% to $135 million • Advanced Diagnostics revenue de ...